No Data
No Data
Optimistic Buy Rating for Liquidia Technologies Driven by Yutrepia's Regulatory Momentum and Promising Study Results
FDA Accepts Liquidia's NDA Resubmission For Yutrepia, Sets PDUFA Date For May 2025
Express News | Liquidia Corp - FDA Sets Pdufa Goal Date of May 24, 2025 for Yutrepia
Express News | Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for Yutrepia™ (Treprostinil) Inhalation Powder
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference
What Does The Future Hold For Liquidia Corporation (NASDAQ:LQDA)? These Analysts Have Been Cutting Their Estimates